Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Opening Session Panel Discussion

Jan

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Opening Session Panel Discussion

Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation

FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

Regulatory Agencies Establish Principles of Good AI Use in Drug Development

Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC